Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Cencora Inc.

Healthcare US COR

276.77USD
2.69(0.98%)

Last update at 2026-06-09T16:02:00Z

Day Range

270.64277.30
LowHigh

52 Week Range

269.07376.92
LowHigh

Fundamentals

  • Previous Close 274.08
  • Market Cap60769.44M
  • Volume296096
  • P/E Ratio37.46
  • Dividend Yield0.70%
  • EBITDA4961.56M
  • Revenue TTM325777.78M
  • Revenue Per Share TTM1679.83
  • Gross Profit TTM 11770.65M
  • Diluted EPS TTM8.34

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax 2258.34M 2003.97M 2160.84M 2183.06M 2221.86M
Minority interest -13.64500M -10.15300M 12.72M 32.28M -4.67600M
Net income 1554.17M 1509.12M 1745.29M 1698.82M 1539.93M
Selling general administrative 6493.84M 5661.11M 5309.98M 4848.96M 3594.25M
Selling and marketing expenses - - - - -
Gross profit 10141.52M 8701.24M 8959.49M 8334.57M 6774.43M
Reconciled depreciation 1068.42M 1118.84M 963.90M 693.89M 514.79M
Ebit 2678.09M 2252.66M 2734.64M 2780.86M 2894.01M
Ebitda 3736.33M 3364.33M 3698.55M 3474.76M 3408.80M
Depreciation and amortization 1058.24M 1111.67M 963.90M 693.89M 514.79M
Non operating income net other - - - - -
Operating income 3647.68M 3040.13M 2340.73M 2366.38M 2354.20M
Other operating expenses 317685.14M 290918.47M 259487.81M 235833.50M 211145.04M
Interest expense 419.75M 248.68M 228.93M 210.67M 182.54M
Tax provision 690.52M 484.70M 428.26M 516.52M 677.25M
Interest income 128.21M 91.69M 228.93M 21.31M 8.47M
Net interest income -291.54800M -156.99100M -228.93100M -210.67300M -174.07400M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 690.52M 484.70M 428.26M 516.52M 677.25M
Total revenue 321332.82M 293958.60M 262173.41M 238587.01M 213988.84M
Total operating expenses 6493.84M 5661.11M 6273.89M 5542.86M 4099.42M
Cost of revenue 311191.30M 285257.36M 253213.92M 230252.44M 207214.41M
Total other income expense net -1389.34300M -1036.15700M -295.83800M -359.78000M -447.87200M
Discontinued operations - - - - -
Net income from continuing ops 1567.81M 1519.27M 1732.58M 1666.54M 1544.61M
Net income applicable to common shares 1554.17M 1509.12M 1745.29M 1698.82M 1539.93M
Preferred stock and other adjustments - - - - -
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 76590.11M 67101.67M 62558.75M 56560.62M 57337.81M
Intangible assets 3774.18M 4001.05M 14005.90M 4332.74M 5256.93M
Earning assets - - - - -
Other current assets 2126.74M 1714.52M 1840.93M 2192.50M 2125.16M
Total liab 74843.03M 66314.93M 61892.46M 56489.34M 56753.39M
Total stockholder equity 1508.02M 645.94M 666.29M -289.78400M 223.35M
Deferred long term liab - - - - -
Other current liab 2391.59M 2262.00M 2353.82M 2214.59M 192.07M
Common stock 2.97M 2.96M 666.29M 2.93M 2.91M
Capital stock 2.97M 2.96M - 2.93M 2.91M
Retained earnings 6534.23M 5417.14M - 2977.65M 1670.51M
Other liab - - - 7514.74M 8064.89M
Good will 13676.52M 9318.03M - 8503.89M 9030.53M
Other assets 2812.78M 2741.75M 3618.85M 1054.26M 1017.60M
Cash 4394.55M 3231.24M 2592.05M 3388.19M 2547.14M
Cash and equivalents 4356.14M 3132.65M 2592.05M 3388.19M 2547.14M
Total current liabilities 57820.54M 54277.05M 48831.20M 43477.96M 41358.64M
Current deferred revenue - - -641.34400M - 2856.41M
Net debt 6353.26M 3421.55M 2195.41M 2314.64M 4136.78M
Short term debt 371.56M 781.10M 641.34M 1070.47M 300.21M
Short long term debt 117.78M 576.33M 641.34M 1070.47M 300.21M
Short long term debt total 10747.81M 6652.80M 4787.46M 5702.83M 6683.92M
Other stockholder equity -4127.80400M -3785.04500M 666.29M -1439.38700M -1004.62400M
Property plant equipment 4087.55M 3323.03M 2135.17M 3079.98M 3230.14M
Total current assets 52239.07M 47717.81M 42798.83M 39589.76M 38802.61M
Long term investments - - - - -
Net tangible assets - - - -13048.18200M -14064.10400M
Short term investments - - - 0.00000M 372.91M
Net receivables 25225.30M 23871.81M 20911.08M 18452.67M 18389.05M
Long term debt 7542.99M 3811.74M 4146.11M 4632.36M 6383.71M
Inventory 20492.48M 18998.83M 17454.77M 15556.39M 15368.35M
Accounts payable 54719.76M 50942.16M 45836.04M 40192.89M 38009.95M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -901.37800M -989.11800M - -1830.97000M -445.44200M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 2603.97M 2428.76M 3418.18M 1761.66M 1793.99M
Deferred long term asset charges - - - - -
Non current assets total 24351.04M 19383.85M 19759.92M 16970.86M 18535.20M
Capital lease obligations - - - - -
Long term debt total 7542.99M 3811.74M 4146.11M 4632.36M 6383.71M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments -4977.29300M -618.09600M -2602.46500M -368.43700M -6141.57700M
Change to liabilities - - - 3320.72M 2049.17M
Total cashflows from investing activities -4977.29300M -618.09600M -2602.46500M -368.43700M -6141.57700M
Net borrowings 3195.67M -385.45200M - -923.10300M 2216.55M
Total cash from financing activities 2249.11M -2330.99400M -2222.27800M -1752.78000M 1952.85M
Change to operating activities - - - -854.72000M 276.14M
Net income 1567.81M 1519.27M 1732.58M 1666.54M 1544.61M
Change in cash 1096.67M 544.99M -840.65000M 523.41M -1527.61800M
Begin period cash flow 3297.88M 2752.89M 3593.54M 3070.13M 4597.75M
End period cash flow 4394.55M 3297.88M 2752.89M 3593.54M 3070.13M
Total cash from operating activities 3875.12M 3484.68M 3911.33M 2703.09M 2666.59M
Issuance of capital stock - - - 0.00000M 0.00000M
Depreciation 1051.08M 448.20M 963.90M 709.84M 514.79M
Other cashflows from investing activities -4309.31200M -130.92300M -2144.10600M 127.88M -5703.36000M
Dividends paid 437.08M 416.17M -398.75200M -391.68700M -366.64800M
Change to inventory -1269.42900M -1479.59900M -2183.36800M -665.37000M -1116.34400M
Change to account receivables -1923.41100M -2784.33900M -2711.78600M -1659.52500M -930.07800M
Sale purchase of stock -435.47100M -1491.36700M -1180.72800M -483.70400M -82.15000M
Other cashflows from financing activities -103.13500M -75.84700M -19.54000M -48.19800M -13.65500M
Change to netincome - - - 434.10M 244.55M
Capital expenditures 667.98M 487.17M 458.36M 496.32M 438.22M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 35.42M 298.69M 874.54M -139.66200M 367.32M
Stock based compensation 147.96M 148.00M - 93.40M 99.59M
Other non cash items 2271.88M 1172.85M 340.31M 176.79M -194.59000M
Free cash flow 3207.14M 2997.51M 3452.97M 2206.77M 2228.37M

Peer Comparison

Sector: Healthcare Industry: Medical Distribution

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
COR
Cencora Inc.		 2.69 0.98% 276.77 37.46 17.70 0.19 31.84 0.20 17.10
MCK
McKesson Corporation		 11.23 1.46% 777.87 17.95 14.53 0.20 5.04 0.22 12.17
CAH
Cardinal Health Inc		 3.91 1.91% 208.39 29.48 17.92 0.20 16.07 0.22 15.67
HSIC
Henry Schein Inc		 1.27 1.63% 79.32 24.12 14.04 0.74 2.50 0.95 13.33
SHPMF
Shanghai Pharmaceuticals Holding Co. Ltd		 - -% 1.46 7.71 5.45 0.03 0.57 0.03 0.88

Reports Covered

Stock Research & News

View All

Profile

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Cencora Inc.

1 West First Avenue, Conshohocken, PA, United States, 19428-1800

Key Executives

Name Title Year Born
Mr. Steven H. Collis Chairman, Pres & CEO 1961
Mr. James F. Cleary Jr. Exec. VP & CFO 1963
Dr. Robert P. Mauch Ph.D., PharmD Exec. VP & COO 1967
Ms. Gina K. Clark Exec. VP and Chief Communications & Admin. Officer 1957
Mr. John G. Chou Exec. VP and Special Advisor to the Chairman & CEO 1956
Mr. Lazarus Krikorian Sr. VP, Chief Accounting Officer & Corp. Controller 1965
Bennett S. Murphy Sr. VP of Investor Relations NA
Ms. Kathy H. Gaddes Exec. VP & Chief Compliance Officer 1963
Ms. Elizabeth S. Campbell Exec. VP & Chief Legal Officer 1975
Ms. Silvana Battaglia Exec. VP & Chief HR Officer 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions